|
nasdaq:cyad
|
878042
|
Apr 14th, 2024 12:00AM
|
Celyad Oncology
|
15K
|
34.00
|
Open
|
|
Apr 13th, 2024 10:54PM
|
Apr 13th, 2024 10:54PM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 13th, 2024 12:00AM
|
Celyad Oncology
|
15K
|
34.00
|
Open
|
|
Apr 12th, 2024 10:45PM
|
Apr 13th, 2024 11:20AM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 12th, 2024 12:00AM
|
Celyad Oncology
|
15K
|
34.00
|
Open
|
|
Apr 11th, 2024 10:49PM
|
Apr 12th, 2024 08:15AM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 11th, 2024 12:00AM
|
Celyad Oncology
|
15K
|
35.00
|
Open
|
|
Apr 10th, 2024 11:22PM
|
Apr 11th, 2024 10:59AM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 10th, 2024 12:00AM
|
Celyad Oncology
|
15K
|
35.00
|
Open
|
|
Apr 9th, 2024 10:52PM
|
Apr 10th, 2024 05:08PM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 9th, 2024 12:00AM
|
Celyad Oncology
|
15K
|
35.00
|
Open
|
|
Apr 8th, 2024 11:03PM
|
Apr 9th, 2024 09:49AM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 8th, 2024 12:00AM
|
Celyad Oncology
|
15K
|
35.00
|
Open
|
|
Apr 7th, 2024 11:29PM
|
Apr 8th, 2024 06:47PM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 7th, 2024 12:00AM
|
Celyad Oncology
|
14K
|
35.00
|
Open
|
|
Apr 6th, 2024 10:59PM
|
Apr 6th, 2024 10:59PM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 6th, 2024 12:00AM
|
Celyad Oncology
|
14K
|
35.00
|
Open
|
|
Apr 5th, 2024 11:00PM
|
Apr 5th, 2024 11:00PM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|
|
nasdaq:cyad
|
878042
|
Apr 5th, 2024 12:00AM
|
Celyad Oncology
|
14K
|
35.00
|
Open
|
|
Apr 4th, 2024 11:27PM
|
Apr 4th, 2024 11:27PM
|
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
|
Open
|
Immuno-Oncology, Cancer, shRNA multiplex, CAR T-cells, Immunotherapy, and NKG2D
|
Open
|
9 rue André Dumont
|
Mont-Saint-Guibert
|
|
BE
|
1435
|
|
Celyad
|
|
|